O
BMRN icon

OppenheimerFunds’s BioMarin Pharmaceuticals BMRN Stock Holding History

OppenheimerFunds’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$16.3M Buy
183,254
+7,735
+4% +$717K 0.02% 583
2018
Q4 		$14.9M Sell
175,519
-2,612
-1% -$248K 0.02% 579
2018
Q3 		$17.3M Hold
178,131
– – 0.02% 621
2018
Q2 		$16.8M Sell
178,131
-1,083,831
-86% -$94.9M 0.02% 625
2018
Q1 		$102M Sell
1,261,962
-55,172
-4% -$4.73M 0.13% 175
2017
Q4 		$117M Sell
1,317,134
-31,239
-2% -$2.72M 0.14% 166
2017
Q3 		$125M Sell
1,348,373
-239,577
-15% -$21.2M 0.15% 155
2017
Q2 		$144M Sell
1,587,950
-81,407
-5% -$7.41M 0.18% 144
2017
Q1 		$147M Sell
1,669,357
-10,020
-0.6% -$891K 0.18% 148
2016
Q4 		$139M Sell
1,679,377
-484,776
-22% -$41.7M 0.18% 145
2016
Q3 		$200M Buy
2,164,153
+95,140
+5% +$8.96M 0.25% 111
2016
Q2 		$161M Buy
2,069,013
+201,629
+11% +$17.1M 0.21% 127
2016
Q1 		$154M Buy
1,867,384
+152,696
+9% +$12.4M 0.2% 126
2015
Q4 		$180M Sell
1,714,688
-120,150
-7% -$12.5M 0.23% 109
2015
Q3 		$193M Sell
1,834,838
-78,910
-4% -$10.5M 0.26% 101
2015
Q2 		$262M Sell
1,913,748
-4,190
-0.2% -$519K 0.3% 88
2015
Q1 		$239M Buy
1,917,938
+150,530
+9% +$15.9M 0.27% 107
2014
Q4 		$160M Sell
1,767,408
-62,440
-3% -$5.19M 0.18% 155
2014
Q3 		$132M Buy
1,829,848
+1,345,578
+278% +$88.4M 0.15% 179
2014
Q2 		$30.1M Sell
484,270
-29,070
-6% -$1.76M 0.03% 475
2014
Q1 		$35M Buy
513,340
+245,040
+91% +$18.1M 0.04% 428
2013
Q4 		$18.9M Buy
268,300
+82,960
+45% +$5.63M 0.02% 575
2013
Q3 		$13.4M Buy
185,340
+92,540
+100% +$6.15M 0.01% 779
2013
Q2 		$5.18M Buy
+92,800
New +$5.78M 0.01% 784

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds's BMRN Position: Q1 2019 in Review

OppenheimerFunds increased its BioMarin Pharmaceuticals (BMRN) stake by 4.4% in Q1 2019, buying an estimated $717K and bringing the position to 183,254 shares worth $16.3M. The position accounts for 0.02% of the portfolio, ranked #583.

OppenheimerFunds first reported a position in BMRN in Q2 2013 and has held it in 24 quarters since. The position peaked at $262M in Q2 2015. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

  • OppenheimerFunds held 183,254 shares of BioMarin Pharmaceuticals worth $16.3M as of Q1 2019.
  • OppenheimerFunds bought 7,735 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $717K.
  • BioMarin Pharmaceuticals made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #583 holding.
  • OppenheimerFunds first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • OppenheimerFunds's BioMarin Pharmaceuticals position peaked at $262M in Q2 2015.
  • 486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.